Solid dispersion improves release of curcumin from nanoparticles: Potential benefit for intestinal absorption

Pinlaor, Somchai; Jantawong, Chanakan; Intuyod, Kitti; Sirijindalert, Thirawat; Pinlaor, Porntip; Pairojkul, Chawalit; Charoensuk, Lakhanawan; Sitthirach, Chutima; Vaeteewoottacharn, Kulthida; Puthongking, Ploenthip; Priprem, Aroonsri

doi:10.1016/j.mtcomm.2020.101999

Cited by 7 publications

(8 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, we used an improved version of curcumin-loaded nanocomplexes (CNCs), known to be safe in mouse and hamster models (Jantawong et al 2021) and with low cytotoxicity to normal broblast and cholangiocarcinoma cell lines (Pinlaor S et al 2021). These CNCs were tested for their ability to retard CCA development in hamsters.…”

Section: Discussionmentioning

confidence: 99%

“…Curcumin-loaded nanocomplexes (CNCs, WellCap® Kaminn, Encapsulation e ciency = 80%, Loading capacity = 28%, particle size 400-1,000 nm) and blank nanocomplexes (BNCs, WellCap® Capsule) powder were obtained from Welltech Biotechnology Co. Ltd. Bangkok, Thailand. CNCs were prepared according to a previously described spray-drying method (Pinlaor S et al 2021).…”

Section: Preparation Of Cncsmentioning

confidence: 99%

See 1 more Smart Citation

Curcumin-loaded nanocomplexes alleviate the progression of fluke-related cholangiocarcinoma in hamsters

Jantawong

Chamgramol

Intuyod

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Curcumin-loaded nanocomplexes (CNCs) previously demonstrated lower toxicity and extended release better than is the case for free curcumin. Here, we evaluated the efficacy of CNCs against opisthorchiasis-associated cholangiocarcinoma (CCA) in hamsters. Method: Dose optimization (dose and frequency) was performed over a one-month period using hamsters, a model that is widely used for study of opisthorchiasis-associated cholangiocarcinoma. In the main experimental study, CCA was induced by a combination of fluke, Opisthorchis viverrini (OV), infection and N-nitrosodimethylamine (NDMA) treatment. Either blank (empty) nanocomplexes (BNCs) or different concentrations of CNCs (equivalent to 10 and 20 mg cur/kg bw) were given to hamsters thrice a week for five months. The histopathological changes, biochemical parameters, and the expression of inflammatory/ oncogenic transcription factors were investigated.Results: The optimization study revealed that treatment with CNCs at a dose equivalent to 10 mg cur/kg bw, thrice a week for one month, led to a greater reduction of inflammation and liver injury induced in hamsters by OV+NDMA than did treatments at other dose rates. Oral administration with CNCs (10 mg cur/kg bw), thrice a week for five months, significantly increased survival rate, reduced CCA incidence, extent of tumor development, cholangitis, bile-duct injury and cholangiofibroma. In addition, this treatment decreased serum ALP and ALT levels and suppressed expression of oncogenic transcription factors including NF- κB and FOXM1. Conclusion: CNCs (10 mg cur/kg bw) attenuate the progression of fluke-related CCA in hamsters.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Preparation Of Cncsmentioning

confidence: 99%

Curcumin-loaded nanocomplexes alleviate the progression of fluke-related cholangiocarcinoma in hamsters

Jantawong

Chamgramol

Intuyod

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…The curcumin powder (97% purity w/w) was purchased from Merck-Schuchardt (Hohenbrunn, Germany). Powdered CNCs (containing 28.6% curcumin by weight) and blank nanocomplexes (BNCs) were obtained as in the previous study [ 26 , 27 ]. Curcumin powder was weighed and dissolved in corn oil, and BNCs and CNCs powders were dispersed in distilled water [ 29 ].…”

Section: Methodsmentioning

confidence: 99%

“…Treatment with nano-curcumin leads to improved glucose indices, lipids, inflammation, and nesfatin in overweight and obese patients with NAFLD [ 25 ]. We also developed a novel nano-encapsulated curcumin based on a polymeric nanocarrier (called curcumin-loaded nanocomplexes, CNCs) that is safe and has no obvious side effects during either short-term or long-term consumption in animal models [ 26 , 27 ]. However, the hepatoprotective effects of CNCs on NASH progression have not been evaluated.…”

Section: Introductionmentioning

confidence: 99%

Curcumin-loaded nanocomplexes ameliorate the severity of nonalcoholic steatohepatitis in hamsters infected with Opisthorchis viverrini

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background Comorbidity of Opisthorchis viverrini (OV) infection and nonalcoholic fatty-liver disease (NAFLD) enhances NAFLD progression to nonalcoholic steatohepatitis (NASH) by promoting severe liver inflammation and fibrosis. Here, we investigated the effect of supplementation with curcumin-loaded nanocomplexes (CNCs) on the severity of NASH in hamsters. Methodology Hamsters were placed in experimental groups as follows: fed standard chow diet (normal control, NC); fed only high-fat and high-fructose (HFF) diet; O. viverrini-infected and fed HFF diet (HFFOV); group fed with blank nanocomplexes (HFFOV+BNCs); groups fed different doses of CNCs (25, 50 and 100 mg/kg body weight: HFFOV+CNCs25; HFFOV+CNCs50; HFFOV+CNCs100, respectively) and a group given native curcumin (HFFOV+CUR). All treatment were for three months. Results The HFF group revealed NAFLD as evidenced by hepatic fat accumulation, ballooning, mild inflammation and little or no fibrosis. These changes were more obvious in the HFFOV group, indicating development of NASH. In contrast, in the HFFOV+CNCs50 group, histopathological features indicated that hepatic fat accumulation, cell ballooning, cell inflammation and fibrosis were lower than in other treatment groups. Relevantly, the expression of lipid-uptake genes, including fatty-acid uptake (cluster of differentiation 36), was reduced, which was associated with the lowering of alanine aminotransferase, total cholesterol and triglyceride (TG) levels. Reduced expression of an inflammation marker (high-mobility group box protein 1) and a fibrosis marker (alpha smooth-muscle actin) were also observed in the HFFOV+CNCs50 group. Conclusion CNCs treatment attenuates the severity of NASH by decreasing hepatic steatosis, inflammation, and fibrosis as well as TG synthesis. CNCs mitigate the severity of NASH in this preclinical study, which indicates promise for future use in patients.

show abstract

“…Incorporation of curcumin into a mucoadhesive polymeric nanocarrier to deliver this payload into the gastrointestinal tract has been particularly promising (Suwannateep et al 2011). Polymeric nanocurcumin has recently been improved by covering particles with xanthan and arabic gums-so-called curcumin-loaded nanocomplexes (CNCs) (Pinlaor et al 2021). CNCs have very low toxicity for biliary epithelial cells and exhibit anti-CCA activity against CCA cell lines (Pinlaor et al 2021).…”

Section: Introductionmentioning

confidence: 99%

Curcumin-loaded nanocomplexes alleviate the progression of fluke-related cholangiocarcinoma in hamsters

et al. 2023

View full text Add to dashboard Cite

Background Curcumin-loaded nanocomplexes (CNCs) previously demonstrated lower toxicity and extended release better than is the case for free curcumin. Here, we evaluated the efficacy of CNCs against opisthorchiasis-associated cholangiocarcinoma (CCA) in hamsters. Method Dose optimization (dose and frequency) was performed over a 1-month period using hamsters, a model that is widely used for study of opisthorchiasis-associated cholangiocarcinoma. In the main experimental study, CCA was induced by a combination of fluke, Opisthorchis viverrini (OV), infection and N-nitrosodimethylamine (NDMA) treatment. Either blank (empty) nanocomplexes (BNCs) or different concentrations of CNCs (equivalent to 10 and 20 mg cur/kg bw) were given to hamsters thrice a week for 5 months. The histopathological changes, biochemical parameters, and the expression of inflammatory/oncogenic transcription factors were investigated. In addition, the role of CNCs in attenuating CCA genesis, as seen in an animal model, was also confirmed in vitro using CCA cell lines. Results The optimization study revealed that treatment with CNCs at a dose equivalent to 10 mg cur/kg bw, thrice a week for 1 month, led to a greater reduction of inflammation and liver injury induced in hamsters by OV + NDMA than did treatments at other dose rates. Oral administration with CNCs (10 mg cur/kg bw), thrice a week for 5 months, significantly increased survival rate, reduced CCA incidence, extent of tumor development, cholangitis, bile duct injury and cholangiofibroma. In addition, this treatment decreased serum ALP and ALT activities and suppressed expression of NF-κB, FOXM1, HMGB1, PCNA and formation of 8-nitroguanine. Treatment of CCA cell lines with CNCs also reduced cell proliferation and colony formation, similar to those treated with NF-κB and/or FOXM1 inhibitors. Conclusion CNCs (10 mg cur/kg bw) attenuate the progression of fluke-related CCA in hamsters partly via a NF-κB and FOXM1-mediated pathway.

show abstract

Solid dispersion improves release of curcumin from nanoparticles: Potential benefit for intestinal absorption

Cited by 7 publications

References 30 publications

Curcumin-loaded nanocomplexes alleviate the progression of fluke-related cholangiocarcinoma in hamsters

Curcumin-loaded nanocomplexes alleviate the progression of fluke-related cholangiocarcinoma in hamsters

Curcumin-loaded nanocomplexes ameliorate the severity of nonalcoholic steatohepatitis in hamsters infected with Opisthorchis viverrini

Curcumin-loaded nanocomplexes alleviate the progression of fluke-related cholangiocarcinoma in hamsters

Contact Info

Product

Resources

About